Long-term health study for people with lymphoma treated with liso-cel
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with follicular lymphoma (grades 1, 2, or 3a) that came back or did not respond to other treatments.
- You have already received at least one infusion of liso-cel (also called Breyanzi) as part of your regular medical care in the United States.
- You are not taking part in any other research study at the time you received liso-cel.
- You did not receive liso-cel for a different type of lymphoma called grade 3b follicular lymphoma.
- You received a standard, approved liso-cel product, not a custom or experimental one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have already received a CAR T-cell therapy called Relma-cel for blood cancers. It aims to understand how they are doing and may involve keeping track of their health over time.
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.